Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company announced in a press release. Specifically, the new drug applications will cover myeloma patients who have received at least four therapies, and failed to respond to at least two immunomodulatory therapies, two proteasome inhibitors, and one CD38 inhibitor. Applications submitted in Singapore and Australia are requesting the addition of two other indications:…
You must be logged in to read/download the full post.
The post Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets appeared first on BioNewsFeeds.